Nervive is developing a breakthrough new product to help stroke victims

I have not seen any research that points to the success for this. So ask your doctor about it.
http://www.akronohio.gov/cms/news/a7890631d5da99d6/index.html

Possibly like this;

City of Akron Press Release
From the desk of stephanie york
Published: 01-08-2014
          Akron, Ohio (January  8, 2014) –  The Akron Development Corporation, through its Akron BioInvestment Funds, LLC, has announced that Nervive, Inc., a biomedical company from Northern California, will be consolidating various business units and opening up new headquarters in Akron, Ohio at the Akron Global Business Accelerator, an initiative of the City of Akron, or other Akron site.
          Nervive has received Akron BioInvestment funding to commercialize its VitalFlow stimulator, a non-invasive medical device that increases blood flow to the brain as an emergency treatment for ischemic stroke patients.  The VitalFlow can treat stroke patients at the earliest opportunity, in the field or immediately upon a patient’s arrival at the hospital, improving the odds of a good clinical outcome by as much as 170%.  This breakthrough treatment could save $518 million in acute healthcare costs and $7.2 billion in lifetime healthcare costs and lost productivity in the U.S. alone.  The Akron BioInvestment funding will help Nervive pursue product development and clinical testing of the VitalFlow.
Stroke is the most common cause of disability and the second most common cause of death worldwide, and the number of its victims and its economic burden is expected to increase into the foreseeable future.  In the U.S., nearly 800,000 cases of stroke occur each year, where as in Europe there are 1.1 million cases of stroke each year.  Worldwide, there are 16.9 million cases of stroke annually of which 5.7 million prove fatal.  The first version of the VitalFlow would be made available to treat stroke patients in approximately 5,500 hospitals in the U.S. and 16,000 hospitals in Europe.  A second, portable version of the VitalFlow would be made available in 48,000 ambulances in the U.S. and 110,000 ambulances in Europe.
          “We created the Akron BioInvestment Funds, LLC in order to attract companies like Nervive and, earlier this year, Quest Medical,” said Mayor Don Plusquellic.  “These companies will expand our biomedical infrastructure and create more jobs for our citizens.”
            Nervive is led by a veteran Chief Executive Officer, Jerry Gibson, who has to date built a team of 9 scientists and product designers.  The company will pursue further product development work with local firms under the direction of Chief Technology Officer Subba Shankar Ph.D., a Case-Western trained biomedical engineer and neuroscientist who has an extensive background in medical device development.  By 2015, Nervive expects to have the first clinical version of the VitalFlow ready for testing in stroke patients, which will be done through research collaboration with Ohio-based hospitals under the direction of Chief Medical Officer and VitalFlow inventor, Dr. Mark Borsody, who is himself a stroke neurologist.
          “Akron provides an excellent location for our global headquarters,” says CEO Gibson, “one that is unique in terms of product development domain experience,  excellent engineering,and executive talent.  Furthermore, the central location provides good access to customers and allows for worldwide production of the VitalFlow.  We came to this decision after considering several options in the U.S. and Europe, and I am confident it will prove to be a wise one.”
          “Ohio is home to several world-class hospitals that are interested in the VitalFlow technology,” adds CMO Borsody, who studied medicine at the Ohio State University and the Cleveland Clinic.  “We intend to first demonstrate the VitalFlow’s benefit in stroke patients right here in Akron.”